I agree that this site is using cookies. You can find further informations here.
X
Plesner, T.
121  results:
Search for persons X
?
1

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INE..:

Facon, T. ; Plesner, T. ; Usmani, S....
HemaSphere.  7 (2023)  S2 - p. 18-19 , 2023
Link: https://doi.org/10.1097/..
 
?
2

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) ..:

Weisel, K. ; Kumar, S. ; Moreau, P....
HemaSphere.  7 (2023)  S2 - p. 14-15 , 2023
Link: https://doi.org/10.1097/..
 
?
3

Proteomic profiling identifies apoptotic deregulation predi..:

Enemark, M. B. H. ; Sørensen, E. F. ; Andersen, M. D....
Hematological Oncology.  41 (2023)  S2 - p. 292-294 , 2023
Link: https://doi.org/10.1002/..
 
?
4

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS..:

Dimopoulos, MA ; Oriol, A ; Nahi, H...
HemaSphere.  6 (2022)  - p. 13-13 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-R..:

Facon, T. ; Kumar, S. K. ; Plesner, T....
HemaSphere.  6 (2022)  - p. 826-827 , 2022
Link: https://doi.org/10.1097/..
 
?
6

Up-front rituximab maintenance improves outcome in patients..:

Madsen, C. ; Clausen, M. R. ; Plesner, T. L....
Blood Advances.  2 (2018)  13 - p. 1562-1571 , 2018
Link: https://doi.org/10.1182/..
 
?
7

DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENAL..:

Bahlis, N.J. ; Moreau, P. ; Nahi, H....
Hematological Oncology.  35 (2017)  S2 - p. 389-389 , 2017
Link: https://doi.org/10.1002/..
 
?
8

Whole-body computed tomography versus conventional skeletal..:

Hillengass, J ; Moulopoulos, L A ; Delorme, S...
Blood Cancer Journal.  7 (2017)  8 - p. e599-e599 , 2017
Link: https://doi.org/10.1038/..
 
?
9

Clinical Implications of Complex Pharmacokinetics for Darat..:

Xu, XS ; Yan, X ; Puchalski, T...
Clinical Pharmacology & Therapeutics.  101 (2017)  6 - p. 721-724 , 2017
Link: https://doi.org/10.1002/..
 
?
10

Improved tumor response and survival outcomes with post-tra..:

Sezer, O. ; Terpos, E. ; Hajek, R....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e129-e130 , 2015
Link: https://doi.org/10.1016/..
 
?
11

Continued improvement in overall survival in elderly multip..:

Abildgaard, N. ; Vangsted, A. ; Gregersen, H....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e189 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Safety and efficacy of first-line treatment with doxorubici..:

Andersen, K.T. ; Hinge, M. ; Segel, E....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e144 , 2015
Link: https://doi.org/10.1016/..
 
?
13

Elotuzumab: serum protein electrophoresis and immunofixatio..:

Dimopoulos, M. ; Lonial, S. ; Casado, L.F....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e267-e268 , 2015
Link: https://doi.org/10.1016/..
 
?
14

Treatment Sequencing Survival Model for Patients with Multi..:

Heeg, B. ; Van Agthoven, M. ; van Beurden-Tan, C....
Value in Health.  17 (2014)  7 - p. A617-A618 , 2014
Link: https://doi.org/10.1016/..
 
?
15

A343 Rapid Stimulation of Bone Formation by Bortezomib in M..:

Plesner, T ; Lund, T ; Soe, K...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S55 , 2009
Link: https://doi.org/10.1016/..
 
1-15